Group 1: Market Overview - The total market capitalization of listed companies in China exceeded 90 trillion yuan at the end of June, marking the highest point in nearly three years [1] - There has been a net decrease of 325 companies with a market value below 2 billion yuan since the beginning of the year [1] - In June, 8 new companies were listed, raising a total of 9.153 billion yuan, while 1 company was delisted [1] Group 2: Regulatory Changes - The Hong Kong Stock Exchange announced a reduction in the minimum price fluctuation for stocks, effective August 4, aimed at lowering trading costs and improving efficiency [2] Group 3: Corporate Developments - BioMap appointed Patrick Zhang as President of Corporate Development, bringing experience from previous roles in major pharmaceutical companies [6] - Huafeng Aluminum signed a five-year raw material purchase contract with Shaanxi Youse Yulin New Materials Group, with a total expected transaction amount exceeding 7.2 billion yuan [7] - Changhua Group received a product purchase contract for carbon-ceramic brake discs, with a total sales amount expected to exceed 100 million yuan over a five-year project lifecycle [7] Group 4: Financial Performance - Zhongke Environmental reported a net profit of 196 million yuan for the first half of the year, a year-on-year increase of 19.83% [8] - WuXi AppTec's net profit for the first half of the year grew by 101.92% to 8.561 billion yuan, with a proposed cash dividend of 3.5 yuan per 10 shares [9] - Sujiao Technology's net profit decreased by 39.54% to approximately 95.39 million yuan, with a proposed cash dividend of 0.2 yuan per 10 shares [10] - Jucheng Co. reported a net profit of 205 million yuan, a significant increase of 43.5% year-on-year, driven by strong sales in specific product lines [11] Group 5: Market Trends - The ChiNext index rose nearly 1%, with over 2,700 stocks gaining in value, particularly in the computing hardware sector, which saw multiple stocks reach historical highs [12]

| 非居民企業 | | | | | --- | --- | --- | --- | | （非中國內地登記地址） | | 10% | 本公司向名列於H股股東名冊上的 | | | | | 非居民企業股東派發中期股息時， | | | | | 有義務代扣代繳企業所得稅，稅率 | | | | | 為10%。任何以非個人股東（包括 | | | | | 香港中央結算（代理人）有限公 | | | | | 司，其他代理人或受託人，或其他 | | | | | 組織及團體）名義登記的H股股份 | | | | | 均被視為非居民企業股東所持的H | | | | | 股股份，其應得的股息將被扣除中 | | | | | 國企業所得稅。 | | 於投資上海證券交易所本公司 | | 10% | 本公司按照10%的稅率代扣所得 | | A股股票的香港聯交所投資者 | | | 稅，並將該代扣事宜向主管稅務機 | | （包括企業和個人） | | | 關辦理扣繳申報。 | | 於上海證券交易所及深圳證券 | | 20% | 本公司按照20%的稅率代扣個人所 | | 交易所投資者（包括企業和個 | | | 得稅。 | | 人）投資香港聯交所本公司H ...

Core Insights - WuXi AppTec (02359) reported an unaudited interim performance for the six months ending June 30, 2025, with revenue of 20.799 billion RMB, a year-on-year increase of 20.6% [1] - The gross profit reached 9.112 billion RMB, up 36% year-on-year, while the net profit attributable to shareholders was 8.287 billion RMB, reflecting a significant increase of 95.5% [1] - The company proposed an interim dividend of 3.5 RMB per 10 shares [1] Revenue Breakdown - The company’s revenue from ongoing operations was 20.41 billion RMB, with significant contributions from various regions: 14.03 billion RMB from U.S. clients (up 38.4%), 2.33 billion RMB from European clients (up 9.2%), 3.15 billion RMB from Chinese clients (down 5.2%), and 0.9 billion RMB from other regions (up 7.6%) [1] Chemical Business Performance - The chemical business generated revenue of 16.3 billion RMB, marking a year-on-year growth of 33.5% [2] - The small molecule drug discovery segment successfully synthesized and delivered over 440,000 new compounds in the past twelve months [2] - The small molecule development and manufacturing (D&M) segment reported revenue of 8.68 billion RMB, a 17.5% increase year-on-year, with a total of 3,409 molecules in the pipeline as of June 30, 2025 [2] TIDES Business Growth - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching 5.03 billion RMB, a remarkable increase of 141.6% [3] - The backlog of TIDES orders grew by 48.8% year-on-year, with a 12% increase in the number of clients served and a 16% increase in the number of molecules served [3] - The company is expanding its peptide production capacity, expecting the total volume of solid-phase synthesis reactors to exceed 100,000L by the end of 2025 [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 支付2025年中期股息分派 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）於2025年3月26日刊 發的通函（「通函」）；(ii)於2025年3月26日刊發的2024年股東週年大會（「2024年股 東週年大會」）通告（「2024年股東週年大會通告」）；及(iii)於2025年4月29日刊發 的2024年股東週年大會投票結果公告（「公告」）。除非文義另有所指，否則本公 告已界定的詞語在通函、2024年股東週年大會通告及公告中具有相同涵義。 授權董事會制定並實施本公司2025年中期股息分派方案已於2024年股東週年大 會上獲股東批准。據此，董事會在授權範圍內宣派截至2025年6月30日止六個 月的中期股息（「2025年中期股息分派」）如下：每10股派發現金股息人民幣3.50 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 截至2025年6月30日止六個月未經審計中期業績公告 財務摘要 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 變動 | | | 人民幣百萬元 | 人民幣百萬元 | | | | （百分比除外）（百分比除外） | | | | 收入 | 20,799.3 | 17,240.9 | 20.6% | | 毛利 | 9,112.2 | 6,700.9 | 36.0% | | 毛利率 | 43.8% | 38.9% | | | 母公司持有者之應佔淨溢利 | 8,287.3 | 4,239.8 | 95.5% | | 母公司持有者之應佔溢利淨利率 | 39.8% | 24.6% | | | 經調整非《國際財務報告準則》之 | | | | | 母公司持有者之應佔淨溢利 ...

Core Viewpoint - WuXi AppTec expects capital expenditures to reach 7-8 billion yuan by 2025, driven by business growth and efficiency improvements [1] - The company anticipates an increase in free cash flow from 4-5 billion yuan to 5-6 billion yuan by 2025 [1] Summary by Category Financial Projections - Expected capital expenditures for 2025 are projected to be between 7 billion and 8 billion yuan [1] - Free cash flow is forecasted to rise from 4 billion-5 billion yuan to 5 billion-6 billion yuan by 2025 [1]

Core Viewpoint - WuXi AppTec reported strong financial performance for the first half of 2025, with significant increases in revenue and profit, driven by a focus on CRDMO business and operational efficiency improvements [1][3][4]. Financial Performance - Total operating revenue reached RMB 20.799 billion, a year-on-year increase of 20.64% [3]. - Total profit amounted to RMB 9.907 billion, reflecting a 96.2% year-on-year growth [3]. - Net profit attributable to shareholders was RMB 8.561 billion, up 101.92% compared to the previous year [3]. - Net profit after deducting non-recurring gains and losses was RMB 5.582 billion, a 26.47% increase [3]. - Net cash flow from operating activities was RMB 7.431 billion, showing a 49.63% rise [3]. Business Segments and Orders - As of June 30, 2025, the company had a backlog of orders amounting to RMB 56.69 billion, a 37.2% increase year-on-year [4]. - Revenue from U.S. clients was RMB 14.03 billion, up 38.4% [4]. - Revenue from European clients was RMB 2.33 billion, a 9.2% increase [4]. - Revenue from Chinese clients was RMB 3.15 billion, down 5.2% [4]. - Revenue from other regions was RMB 0.90 billion, up 7.6% [4]. Future Outlook - The company expects revenue growth for its ongoing business to return to double-digit growth, with an adjusted growth rate of 13%-17% [4]. - Overall revenue guidance for the year has been raised to a range of RMB 42.5 billion to RMB 43.5 billion [4].

证券代码：603259 证券简称：药明康德 公告编号：临 2025-051 无锡药明康德新药开发股份有限公司 2025 年度提质增效重回报行动方案进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"公司"或"药明康德"） 为践行"以投资者为本"的发展理念，提升上市公司经营质量、规范治理运作水 平，促进上市公司长期可持续发展、增强投资者回报，维护公司全体股东利益， 公司结合自身发展愿景与战略、经营情况及财务状况，制定了 2025 年度提质增 效重回报行动方案。现将 2025 年上半年度公司落实该行动方案的进展情况报告 如下： 一、 聚焦主营业务，保持公司持续盈利能力 公司为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务， 在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的"CRDMO"业 务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的 治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试 验研发等领域。 过去 20 年 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-050 无锡药明康德新药开发股份有限公司 关于变更董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）董事会于近日 收到本公司董事会秘书张远舟先生的书面申请报告，张远舟先生因工作调整申请 辞去本公司董事会秘书的职务。相关辞任报告自送达本公司董事会时生效。 | 姓名 | 离任职务 | 离任时间 | | 原定任期 到期日 | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 股子公司任职 | （如适用） | 毕的公开 | | | | | | | | | | 承诺 | | | | | | | | | 董事会与 | | | | | 年 2025 | 7 | 2026年5月 | | | 证券合规 | | | 张远舟 ...

二、监事会会议审议情况 （一）审议通过《关于公司 2025 年半年度报告、报告摘要及 2025 年半年度 业绩公告的议案》 证券代码：603259 证券简称：药明康德 公告编号：临 2025-048 无锡药明康德新药开发股份有限公司 第三届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 7 月 14 日向本公司全体监事发出会议通知及会议材料，以现场结合通讯 表决方式于 2025 年 7 月 28 日在公司会议室召开第三届监事会第十三次会议。本 次监事会会议应出席监事3人，实际出席监事3人，会议由监事会主席Harry Liang He（贺亮）主持。本次监事会符合《中华人民共和国公司法》和《无锡药明康 德新药开发股份有限公司章程》（以下简称"《公司章程》"）关于召开监事会 会议的规定。 （二）审议通过《关于公司 2025 年中期利润分配方案的议案》 本公司监事会认为，公司 2025 年中期利润分配方 ...